🇺🇸 Sitagliptin + Metformin in United States

163 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 23 reports (14.11%)
  2. Diabetic Ketoacidosis — 19 reports (11.66%)
  3. General Physical Health Deterioration — 18 reports (11.04%)
  4. Vomiting — 18 reports (11.04%)
  5. Diarrhoea — 17 reports (10.43%)
  6. Acute Kidney Injury — 16 reports (9.82%)
  7. Drug Ineffective — 15 reports (9.2%)
  8. Anaemia — 14 reports (8.59%)
  9. Lactic Acidosis — 12 reports (7.36%)
  10. Hyperkalaemia — 11 reports (6.75%)

Source database →

Sitagliptin + Metformin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Diabetes approved in United States

Frequently asked questions

Is Sitagliptin + Metformin approved in United States?

Sitagliptin + Metformin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sitagliptin + Metformin in United States?

Baylor College of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.